Lisaftoclax

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaMyelodysplastic SyndromeMantle Cell LymphomaT-Cell Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia (AML)Mantle Cell Lymphoma (MCL)

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Lisaftoclax

Ascentage Pharma Group Inc.

Phase 3

12

Blenoxane

SSequus Pharmaceuticals

Preclinical

253

Oncaspar

SServier

Preclinical

154

Zofran

Novartis

Preclinical

25

Norvir

AbbVie

Preclinical

16

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

47

Tafasitamab

Incyte

Preclinical

78

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

19

Kenalog

BBausch Health Americas, Inc.

Preclinical

110

Nuvigil

NNuvo Research GmbH

Preclinical

1Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Mantle Cell Lymphoma1 trial

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Recruiting·RRuijin Hospital·Phase 2·NCT07272499·25 enrolled

Relapsed/Refractory AML1 trial

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Recruiting·Ascentage Pharma Group Inc.·Phase 1/2·NCT04501120·458 enrolled

T-cell acute lymphoblastic leukemia1 trial

A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07428486·24 enrolled

CLL/SLL1 trial

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Recruiting·Ascentage Pharma Group Inc.·Phase 1·NCT04215809·144 enrolled

Myelodysplastic Syndrome1 trial

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Recruiting·Ascentage Pharma Group Inc.·Phase 3·NCT06641414·490 enrolled

7 more indications

Immunochemotherapy1 trial

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Recruiting·Ascentage Pharma Group Inc.·Phase 3·NCT06319456·344 enrolled

Lymphoma1 trial

Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07459608·75 enrolled

Phase IB1 trial

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07398638·122 enrolled

Treatment1 trial

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07255963·29 enrolled

Acute Myeloid Leukemia (AML)1 trial

Maintenance Therapy With Lisaftoclax Plus Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse: A Multicenter, Open-Label, Randomized Controlled Trial

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 3·NCT07686965·191 enrolled

Mantle Cell Lymphoma (MCL)1 trial

A Prospective Phase 2 Study of Lisaftoclax Plus Pirtobrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma After Failure of BTK-Targeted Therapy

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07684950·45 enrolled

Acute Promyelocytic Leukemia (APL)1 trial

Lisaftoclax for Prevention of Differentiation Syndrom (DS) in Acute Promyelocytic Leukemia (APL) Patients : An Open-lable, Single-arm, Multicenter, Phase Ⅱ Clinical Trail

Not yet recruiting·TThe Affiliated People's Hospital of Ningbo University·Preclinical·NCT07597941·20 enrolled

Details

Drug Info

Related News